Form 4: Organon & Co. Executive Granted Stock Options and Restricted Stock Units

Juan Camilo Arjona Ferreira, Head of R&D & CMO at Organon & Co., received stock options and restricted stock units (RSUs) on March 29, 2024, according to a Form 4 filing.

Summary

• Juan Camilo Arjona Ferreira, Head of R&D & CMO at Organon & Co., filed a Form 4 indicating changes in beneficial ownership.
• On March 29, 2024, Mr. Arjona Ferreira was granted 26,595 restricted stock units (RSUs) and 108,932 stock options.
• The RSUs represent a contingent right to receive one share of Organon common stock for each RSU.
• The RSUs vest in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027.
• The stock options have an exercise price of $18.80 and vest in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral to slightly positive signal.

Positives

• The grant of RSUs and stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The vesting schedule of the RSUs and stock options suggests a focus on long-term performance and retention of the executive.

Industry Context

Granting stock options and RSUs is a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders. This is a standard compensation practice to attract and retain top talent.

Comparison to Industry Standards

• Stock option and RSU grants are common compensation tools in the pharmaceutical industry.
• Companies like Pfizer, Merck, and Johnson & Johnson also utilize similar equity-based compensation plans for their executives.
• The vesting schedules are fairly standard, typically ranging from three to five years.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with long-term value creation.
• Employees may see this as a positive sign of investment in leadership.

Key Dates